Zentalis Pharmaceuticals, Inc. (ZNTL)Healthcare | Biotechnology | San Diego, United States | NasdaqGM
4.64 USD
-0.38
(-7.570%) ⇩
(April 17, 2026, 4 p.m.
EDT)
After hours: 4.75 +0.11 (2.349%) ⇧ (April 17, 2026, 7:49 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:13 a.m. EDT
ZNTL faces a severe gamma squeeze risk with massive put OI at $2.00 and $1.00 creating a thick 'dam' for the stock to break through in the short term. While the catalyst-driven rally is interesting, the premium sell-side pressure in the options chain makes any breakout attempt fragile. Without a massive volume spike to overcome the put OI at $2.50 and below, the stock offers poor risk-reward for a near-term momentum play; the high autocorrelation/mean-reversion stats on the forecast model further suggest a low probability of a sustained trend in the next 45 days, aligning with the heavy hedge positioning. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.073319 |
| AutoETS | 0.132394 |
| MSTL | 0.146662 |
| AutoTheta | 0.419641 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 3.30 |
| Ljung-Box p | 0.450 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 9.41 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 18.305 |
| Market Cap | 329,119,904 |
| Forward P/E | -2.98 |
| Beta | 1.66 |
| Website | https://zentalis.com |
As of April 19, 2026, 12:13 a.m. EDT: Options activity shows heavy put positioning relative to open interest (OI) due strikes below the current price of $4.64, particularly at the $2.00 and $1.00 levels, indicating strong downside protection hedging by major holders. This bears a 'put compress' effect. While there is some ATM OI at near-term expirations, the sheer volume at OTM puts dilutes the bullish intraday signals from the $5.00 strike. The high implied volatility (IV) at deep OTM strikes suggests market pricing in a high probability of a move lower or significant volatility event avoidance strategies.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.4117646 |
| Address1 | 10,275 Science Center Dr. |
| Address2 | Suite 200 |
| All Time High | 87.19 |
| All Time Low | 1.01 |
| Ask | 4.67 |
| Ask Size | 2 |
| Average Analyst Rating | 2.1 - Buy |
| Average Daily Volume10 Day | 7,947,600 |
| Average Daily Volume3 Month | 1,824,172 |
| Average Volume | 1,824,172 |
| Average Volume10Days | 7,947,600 |
| Beta | 1.659 |
| Bid | 4.58 |
| Bid Size | 2 |
| Book Value | 3.129 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.64 |
| Current Ratio | 6.926 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 5.23 |
| Day Low | 4.38 |
| Debt To Equity | 18.305 |
| Display Name | Zentalis Pharmaceuticals |
| Earnings Timestamp | 1,774,555,200 |
| Earnings Timestamp End | 1,778,788,800 |
| Earnings Timestamp Start | 1,778,788,800 |
| Ebitda | -140,136,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.876 |
| Enterprise Value | 122,803,912 |
| Eps Current Year | -1.77 |
| Eps Forward | -1.555 |
| Eps Trailing Twelve Months | -1.91 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.8881 |
| Fifty Day Average Change | 1.7519 |
| Fifty Day Average Change Percent | 0.6065926 |
| Fifty Two Week Change Percent | 241.17647 |
| Fifty Two Week High | 6.95 |
| Fifty Two Week High Change | -2.31 |
| Fifty Two Week High Change Percent | -0.3323741 |
| Fifty Two Week Low | 1.13 |
| Fifty Two Week Low Change | 3.5099998 |
| Fifty Two Week Low Change Percent | 3.1061945 |
| Fifty Two Week Range | 1.13 - 6.95 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,585,920,600,000 |
| Float Shares | 48,666,479 |
| Forward Eps | -1.555 |
| Forward P E | -2.983923 |
| Free Cashflow | -75,869,504 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 106 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.22353001 |
| Held Percent Institutions | 0.63202 |
| Implied Shares Outstanding | 70,931,016 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California. |
| Long Name | Zentalis Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 329,119,904 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_647536411 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -137,060,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 328,410,604 |
| Number Of Analyst Opinions | 8 |
| Open | 5.17 |
| Operating Cashflow | -125,247,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 212 433 3791 |
| Post Market Change | 0.109000206 |
| Post Market Change Percent | 2.3491426 |
| Post Market Price | 4.749 |
| Post Market Time | 1,776,469,785 |
| Previous Close | 5.02 |
| Price Eps Current Year | -2.6214688 |
| Price Hint | 4 |
| Price To Book | 1.4829018 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.726 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.11111 |
| Region | US |
| Regular Market Change | -0.38 |
| Regular Market Change Percent | -7.56972 |
| Regular Market Day High | 5.23 |
| Regular Market Day Low | 4.38 |
| Regular Market Day Range | 4.38 - 5.23 |
| Regular Market Open | 5.17 |
| Regular Market Previous Close | 5.02 |
| Regular Market Price | 4.64 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 2,284,230 |
| Return On Assets | -0.24481001 |
| Return On Equity | -0.49535 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 70,931,016 |
| Shares Percent Shares Out | 0.060100004 |
| Shares Short | 4,260,634 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 3,775,935 |
| Short Name | Zentalis Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0753 |
| Short Ratio | 6.76 |
| Source Interval | 15 |
| State | CA |
| Symbol | ZNTL |
| Target High Price | 10.0 |
| Target Low Price | 2.0 |
| Target Mean Price | 6.25 |
| Target Median Price | 5.5 |
| Total Cash | 245,892,992 |
| Total Cash Per Share | 3.467 |
| Total Debt | 39,577,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.91 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.9777 |
| Two Hundred Day Average Change | 2.6622999 |
| Two Hundred Day Average Change Percent | 1.3461596 |
| Type Disp | Equity |
| Volume | 2,284,230 |
| Website | https://zentalis.com |
| Zip | 92,121 |